Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan medoxomil versus candesartan cilexetil in symptomatic chronic heart failure
2007-003060-22Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2008
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic heart failure (CHF) comparing Olmesartan medoxomil with Candesartan cilexetil (2 arms). Primary endpoint: Absolute BNP change from baseline to week 24. Started Feb 2008; status: completed.
02
Drugs
olmesartancandesartan cilexetil
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on 2007-003060-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003060-22.